BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32373960)

  • 1. IPO5 promotes malignant progression of esophageal cancer through activating MMP7.
    Li XF; Aierken AL; Shen L
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4246-4254. PubMed ID: 32373960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFAIP8 regulates cisplatin resistance through TAF-Iα and promotes malignant progression of esophageal cancer.
    Zhang DL; Yang N
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4775-4784. PubMed ID: 32432789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation.
    Zhang W; Lu Y; Li X; Zhang J; Lin W; Zhang W; Zheng L; Li X
    J Exp Clin Cancer Res; 2019 Jul; 38(1):296. PubMed ID: 31288861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IPO5 Mediates EMT and Promotes Esophageal Cancer Development through the RAS-ERK Pathway.
    Li M; Li X; Chen S; Zhang T; Song L; Pei J; Sun G; Guo L
    Oxid Med Cell Longev; 2022; 2022():6570879. PubMed ID: 36120598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA UNC5B-AS1 promotes malignant progression of prostate cancer by competitive binding to caspase-9.
    Tan SF; Ni JX; Xiong H
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2271-2280. PubMed ID: 32196578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA CASC11 promotes the development of esophageal carcinoma by regulating KLF6.
    Chen SG; Wang CH; He RQ; Xu RY; Ji CB
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8878-8887. PubMed ID: 31696474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4.
    Liao XH; Wang Y; Zhong B; Zhu SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3143-3151. PubMed ID: 32271432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD82/KAI1 inhibits invasion and metastasis of esophageal squamous cell carcinoma via TGF-β1.
    Zeng TD; Zheng B; Zheng W; Chen C
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5928-5937. PubMed ID: 30280774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
    Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA DUXAP8 regulates proliferation and invasion of esophageal squamous cell cancer.
    Xu LJ; Yu XJ; Wei B; Hui HX; Sun Y; Dai J; Chen XF
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2646-2652. PubMed ID: 29771416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
    Ma CX; Gao WC; Tian L
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-487a promotes proliferation of esophageal cancer cells by inhibiting p62 expression.
    Ma JB; Hu SL; Zang RK; Su Y; Liang YC; Wang Y
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1502-1512. PubMed ID: 30840272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a.
    Xu L; Hou TJ; Yang P
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6505-6515. PubMed ID: 31378890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
    Liu FH; Cui YP; He YK; Shu RH
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA HOTAIR promotes colon cancer development by down-regulating miRNA-34a.
    Peng CL; Zhao XJ; Wei CC; Wu JW
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5752-5761. PubMed ID: 31298326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-597 inhibits NSCLC progression through negatively regulating CDK2 expression.
    Yu DJ; Li YH; Zhong M
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4288-4297. PubMed ID: 32373965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LINC00657 promotes malignant progression of oral squamous cell carcinoma via regulating microRNA-150.
    Xu FY; Xu X; Hu XD
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2482-2490. PubMed ID: 32196599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5.
    Gao W; Lu YX; Wang F; Sun J; Bian JX; Wu HY
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7874-7883. PubMed ID: 31599412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA GClnc1 promotes progression of colorectal cancer by inhibiting p53 signaling pathway.
    Dong YX; Pang ZG; Zhang JC; Hu JQ; Wang LY
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5705-5713. PubMed ID: 31298323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA SNHG20 promotes the development of laryngeal squamous cell carcinoma by regulating miR-140.
    Li Y; Xu J; Guo YN; Yang BB
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3401-3409. PubMed ID: 31081112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.